☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
maat pharma
MaaT Pharma to Highlight Data from the Early Access Program of MaaT013 to Treat Acute Graft-Versus-Host Disease (aGvHD) at EBMT 20...
April 15, 2024
MaaT Pharma Reports the First Patient Dosing of MaaT033 in P-IIb Trial for Blood Cancer Patients
November 6, 2023
MaaT Pharma Receives Positive Opinion from DSMB for MaaT013 in P-III Trial to Treat Graft Versus Host Disease (GvHD)
October 26, 2023
The US FDA Lifts Clinical Hold for MaaT Pharma’s MaaT013 to Treat Acute Graft-versus-Host Disease
April 24, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.